clinical practice guideline; this article published in the british medical journal, summarizes the current state of medical research about chronic pain. Abstract Clinical question What is the role of medical cannabis or cannabinoids for people living with chronic pain due to cancer or non-cancer causes? Current practice Chronic pain is common and distressing and associated with considerable…
The SRF documentary on Medical Cannabis provides an overview on the current market situation Key takeouts: good results on patients using the medicine high prices for patient due to 1 company dominant position flowers are not yet available as medicine (it will only be available with the #pilotprojects medical Cannabis still need to evolve from…
March 24th 2022 – General decision of the Swiss Chemicals Notification Authority concerning the placing on the market of fragrances / perfume oil containing CBD, pursuant to Art. 10 (1) and (2) in connection with Art. 1 (1) to (3) of the Pest Control Products Act. A Federal decision on banning CBD from fragrances (chemical…
Starting this summer, it will be easier to get a prescription for medical cannabis. But watch your wallet, because it won’t be automatically reimbursed. Cannabis-based medicines will soon be available by prescription, without the need for exceptional authorization from the Federal Office of Public Health (FOPH). This legislative change will probably come into force in…
On February 1st 2022, the Swiss Association of Cantonal Chemists, announced in a press release that, in Switzerland, the vast majority of products sold containing the cannabis extract cannabidiol (CBD) do not meet legal requirements. It was relayed across many media channels, such as swissinfo stating that Most CBD cannabis products fail to meet standards. However, these findings do not apply to the medical/therapeutic cannabis.
Bern, 25.08.2021 – At its meeting on August 25, 2021, the Federal Council opened the consultation on the implementation of the amendment to the Narcotics Act (BetmG) passed by Parliament. The amendment is intended to facilitate access to treatments with therapeutic cannabis. In the future, a prescription will no longer require the granting of an exceptional authorization from the Federal Office of Public Health (FOPH). Cannabis for consumption purposes, on the other hand, will continue to be prohibited.
Trends and Developments The current regulatory environment surrounding cannabinoid-based products in Switzerland is unfortunately still marked by a high degree of uncertainty, due both to vague legislative requirements and heterogenous, sometimes arbitrary, enforcement. However, with the rise of public awareness of the general benefits of the cannabis plant as a result of the cannabidiol (CBD)…
Implementation guide by the technical platform for delimitation issues of the FOPH, the FSVO and Swissmedic Products containing cannabidiol (CBD) are gaining popularity in Switzerland. Unlike THC (tetrahydrocannabinol), CBD is not subject to the Narcotics Act because it does not produce a comparable psychoactive effect. However, this does not mean that CBD can simply be…
Visit the new educational event Cannabis as medicine – «From plant to patient». Implementation: 01.05.2021 – 30.06.2021 (on demand until 31.12.2021) Type: e-learning + online workshop (05.06.2021) Costs: CHF 350 Accreditations (among others): FPH: 100, accredited for continuing education FPH Offizin (role 1.2) and continuing education. SDV: requested SGAIM: 4 points for workshop + up…
Berne, 31.03.2021 – Le Conseil fédéral a adopté, lors de sa séance du 31 mars 2021, l’ordonnance portant sur les essais pilotes de remise contrôlée de cannabis à des fins non médicales. Le texte précise les conditions strictes dans lesquelles les études pourront être menées. L’objectif de ces essais est de fournir une base scientifique…
No products in the cart.